Kornimate/medical-research-clean huggingface dataset:
study of cp-751,871 in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced non-small cell lung cancer

Conditions: Carcinoma, Non-Small-Cell Lung

Summary: cp 751,871 is a fully human monoclonal antibody against the insulin-like growth factor 1 receptor (igf-1r). preclinical and clinical data indicate that cp 751,871 augments the anti-tumor activity of chemotherapy. this study will identify the maximal tolerated dose of cp 751,871 (or the maximal feasible dose) in combination with standard gemcitabine-cisplatin chemotherapy for the treatment of advanced non-small cell lung cancer.


Eligibility criteria:
inclusion criteria: * histologically or cytologically proven diagnosis of stage iiib (n3 and/or t4) or stage iv non-small cell lung cancer in patients 18-year-old or older, with eastern cooperative oncology group (ecog) performance status of 0 or 1 not amenable to curative surgery or radiation therapy and an adequate organ function (bone marrow, hepatic, renal, and cardiac) within 14 days prior to enrollment. exclusion criteria: * any prior treatment for non-small cell lung cancer including chemotherapy, biologic response modifiers or therapy with any investigational agents. * patients with known brain metastases, spinal cord compression, uncontrolled superior vein cava syndrome or carcinomatous meningitis. * patients with gastrointestinal abnormalities including active gastrointestinal bleeding, pre-diabetes (pre-fasting glycemia \> 120 g/dl and/or glycosylate haemoglobin level \> 7.5%), known hiv or aids-related illness, significant active cardiac disease or receiving chronic steroid therapy or concurrent use of growth hormones or growth hormone inhibitors or aminoglycoside antibiotics should be excluded from the study.
experienced chinese herbal formulas on pediatric asthma

Conditions: Childhood Asthma

Summary: the purpose of this study is conducting a randomized, single blind, controlled intervention trial to observe the therapeutic effect of experienced chinese herbal formulas based on different stages and different symptoms in pediatric asthma.

pediatric bronchial asthma is a common disease that severely threatens physical and mental health of children. it's urgent to explore effective ways to alleviate the pain caused by asthma. in our research, 160 asthmatic children are randomly divided into a chinese medication group (80 cases) and a western medication control group(80 cases). patients in the chinese medication group are treated with a series of experienced chinese herbal formulas, whereas the western medication control group received a leukotriene receptor antagonist and a bronchial relaxant. the chinese medicine syndromes and western medicine symptoms are scored. pulmonary function and asthma control test score will be applied in this study. we evaluate the situation of asthma from different aspects, including index of pulmonary function and score of asthma control test. real-time pcr was used to determine the mrna expression levels of some inflammatory mediators in peripheral.

Eligibility criteria:
inclusion criteria: * patients were included if they (a) were satisfying the above-mentioned diagnostic criteria with pediatric asthma and cough variation asthma, (b) aged 3-12 years, and (c) were with pattern of phlegm-heat obstruction and cold fluid-retention in lungs at the acute stage, or with pattern of lung-spleen deficiency and kidneyqideficiency at the remission stage of asthma based on traditional chinese medicine syndrome differentiation diagnosis. exclusion criteria: * patients were excluded if they had congenital respiratory system diseases, tumors, immunodeficiency diseases, or cardiovascular diseases.

Keywords: traditional chinese medicine randomized controlled trial
phase ii open-label pilot study of v3381 in chronic cough

Conditions: Cough

Summary: the investigators hypothesise that cough reflex hypersensitivity, demonstrated in chronic cough patients, is due to a phenomenon known as central sensitisation. central sensitisation is a hyper-excitability of the sensory nerves as they join the central nervous system, and is believed to be mediated by the n-methyl-d-aspartate (nmda) receptor\[1-3\].


Eligibility criteria:
inclusion criteria: * male or female 18-75 years of age * females must be of non child-bearing potential * chronic cough ( \> 8 weeks) * normal chest x-ray * normal lung function * idiopathic or treatment resistant cough- exclusion criteria: * recent upper respiratory tract infection (\<4 weeks) * pregnancy/breast-feeding * current smokers or ex-smokers with \ 10 pack years * current treatment with ace inhibitors. * drug or alcohol abuse * uncontrolled hypertension (i.e., \>140/90 mmhg despite adequate medical therapy). * any cardiovascular condition that would be a contra-indication to the use of sympathomimetic amines (e.g. active angina). * any clinically significant neurological disorder * prior renal transplant, current renal dialysis. * any clinically significant or unstable medical or psychiatric condition that would interfere with the patient's ability to participate in the study. * increased risk of seizures. * any malignancy in the past 2 years (with the exception of basal cell carcinoma). * use of opioids, anticonvulsants, antidepressants (particularly mao inhibitors). * any clinically significant abnormal laboratory test result(s). * serum creatinine laboratory value greater than 1.5 x upper limit of normal (uln) reference range (after adjustment for age) or estimated creatinine clearance \<60 ml/min. * total bilirubin greater than upper limit of normal reference range (with the exception of gilbert's syndrome) and/or alanine transaminase (alt) \>1.5 times upper limit of normal reference ranges (after adjustment for age).

Keywords: chronic cough indantadol
comparing supplemental topical agents for the treatment of acute radiation dermatitis in patients with breast cancer

Conditions: Breast Ductal Carcinoma In Situ; Invasive Breast Carcinoma

Summary: this clinical trial compares two supplemental topical agents (aquaphor and miaderm) for the treatment of acute radiation dermatitis in patients with breast cancer undergoing radiation therapy. radiation dermatitis is a radiation-induced skin reaction which can cause itching, swelling, pain, and general discomfort. aquaphor is a commonly available, inexpensive, petrolatum-based multi-purpose ointment designed to protect and sooth extremely dry skin, chapped lips, cracked hands and feet, minor cuts and burns, and many other skin irritations. miaderm is a water-based cream and contains ingredients like calendula, hyaluronate, and aloe vera which may help reduce occurrence and severity of radiation dermatitis. both are commonly recommended and used by breast cancer patients undergoing external beam radiation therapy (ebrt). however, it is not known whether one is better than the other in treating or preventing radiation dermatitis.

primary objective: i. determine the efficacy of miaderm compared to aquaphor in the treatment and/or prevention of radiation dermatitis caused by ebrt in breast cancer patients undergoing ebrt to the breast/chest wall. secondary objective: i. determine quality of life (qol) and need for additional concomitant therapies to address dermatitis in breast cancer patients undergoing ebrt to the breast/chest wall using miaderm compared to aquaphor. outline: patients are randomized to 1 of 2 arms. arm i: beginning on day 1 of radiation therapy, patients apply aquaphor twice daily (bid), but not within the four hours before ebrt, to the irradiated field until 2 weeks following completion of ebrt. arm ii: beginning on day 1 of radiation therapy, patients apply miaderm bid, but not within the four hours before ebrt, to the irradiated field until 2 weeks following completion of ebrt. after completion of study treatment, patients are followed up at 2 weeks and then at 90-120 days.

Eligibility criteria:
inclusion criteria: * documented informed consent of the participant and/or legally authorized representative. * age \> 18 years. * undergoing external beam radiation therapy (ebrt) to the breast or chest wall following surgical resection (lumpectomy or mastectomy) for ductal carcinoma in situ (dcis) or invasive breast cancer using either conventional fractionation or hypofractionation. exclusion criteria: * partial breast irradiation. * prior radiation overlapping with the intended radiotherapy field. * history of systemic radiation sensitivity diseases (xeroderma pigmentosum, ataxia telangiectasia). * extreme hypofractionation (less than 15 fractions of radiation). * palliative treatment. * patient intention to use topical product other than aquaphor or miaderm. * inflammatory breast cancer, skin involvement, planned use of bolus.
hysteroscopy assisted suction curettage for early pregnancy loss

Conditions: Retained Products of Conception; Intrauterine Adhesion

Summary: retained products of conception (rpoc) and intrauterine adhesions (iua) may occur following suction curettage for early miscarriage and cause secondary infertility, recurrent pregnancy loss and pregnancy complications. the aim of this study is to investigate whether adding hysteroscopy to suction curettage reduces the rates of rpoc and iua.

this is a descriptive, prospective study. women aged 18-40 years admitted for surgical evacuation in cases of early missed abortion in a single university affiliated medical center are being recruited. all procedures performed under general anesthesia following cervical ripening with vaginal misoprostol. before the evacuation, a diagnostic hysteroscopy was performed to identify the pregnancy's implantation wall. subsequently, ultrasound guided suction and curettage directed to the implantation wall is done. finally, the uterine cavity is evaluated by hysteroscopy for rpoc. participants are scheduled for follow-up diagnostic office hysteroscopy 2 months after termination of pregnancy for assessment of iua and rpoc. however, due to restrictions on elective surgical procedures brought on by the covid-19 pandemic, the follow-up hysteroscopy examination was postponed until 5 to 6 months after termination of pregnancy.

Eligibility criteria:
inclusion criteria: * women aged 18-40 years who were admitted to the gynecology emergency department at our institution with early miscarriage up to 12 weeks and 6 days of gestation, and choose surgical evacuation over medical treatment exclusion criteria: * incomplete and complete abortions, gestational age\>13 weeks of gestation, suspected molar pregnancy and patients' contraindications for general anesthesia.

Keywords: intrauterine adhesions hysteroscopy retained products of conception
testing psychosocial treatment planning methods for youth anxiety and depression

Conditions: Anxiety Disorders; Depressive Disorder

Summary: youth depression and anxiety represent a serious public health concern, with affected youth often experiencing social, familial, and academic impairment. research evidence supports a growing array of effective treatments for youth depression and anxiety, yet as the collection of evidence-based treatments expands, so do the challenges of utilizing the evidence: clinicians must be able to (1) access, integrate, and apply the available evidence, and (2) engage in a collaborative process with each family to develop a plan that is responsive to each family's unique characteristics, preferences, and goals. engaging caregivers and youths as active collaborators in the treatment planning process is a patient-centered approach with the potential to improve the process and outcome of youth mental health care by facilitating the personalization of established evidence-based treatment approaches. such collaboration, frequently referred to as shared decision-making (sdm), is a hallmark of evidence-based practice and a key feature of federal guidelines for health care delivery. however, despite growing rhetorical support for sdm, empirical support is lacking, particularly in the area of youth mental health treatment. the absence of such research is unfortunate, given the potential for sdm to facilitate the dissemination and implementation of evidence-based treatments, and to personalize the use of established treatments to increase acceptability, retention, satisfaction, and overall effectiveness. the present project tests the feasibility and acceptability of sdm through a pilot randomized controlled trial of 40 youths (ages 7-15) meeting diagnostic criteria for an anxiety or depressive disorder. the trial will compare an evidence-based treatment that is planned collaboratively with youths and caregivers using the sdm protocol, to an evidence-based treatment that is planned by the clinician and supervisor using pretreatment assessment data. eligible youths will received up to 26 treatment sessions at no cost and complete assessments prior to the start of treatment, at the end of treatment, and six months following the end of treatment.


Eligibility criteria:
inclusion criteria: * a current dsm-5 principal diagnosis of a major depressive disorder, dysthymic disorder, generalized anxiety disorder, separation anxiety disorder, social phobia, or specific phobia * if receiving psychiatric medication, dose will be stable for at least 3 months at enrollment with ability to maintain medication * youth and caregiver speak fluent english exclusion criteria: * active suicidality * history of severe physical or mental impairments (e.g., mental retardation, autism spectrum disorders) in youth or caregiver * participation in additional psychosocial treatment

Keywords: anxiety depression childhood therapy treatment medical decision making
registry of patients undergoing cryoablation for early stage breast cancer

Conditions: Early Stage Breast Carcinoma

Summary: this study evaluates the side effects and outcomes of patients who undergo cryoablation for early stage breast cancer.

primary objective: i. to obtain observational real-life data of patients who choose this non-conventional treatment and to follow their outcomes. outline: this is an observational study. patients have their medical records reviewed on study.

Eligibility criteria:
inclusion criteria: * patients undergoing cryoablation for breast cancer
c-met second-line hepatocellular carcinoma

Conditions: Carcinoma, Hepatocellular

Summary: this is a phase 1b/2, multicenter, single arm trial to assess the efficacy, safety, and pharmacokinetics (pk) of msc2156119j as monotherapy in subjects with met+ advanced hepatocellular carcinoma (hcc) with child pugh class a liver function who have failed sorafenib treatment.


Eligibility criteria:
inclusion criteria: * histologically confirmed hcc * child pugh class a liver function score * for phase 2 only: met+ status * male or female, 18 years of age or older * measurable disease in accordance with response evaluation criteria in solid tumors (recist) version 1.1 * eastern cooperative oncology group (ecog) performance status (ps) 0-1 (inclusive) * availability of a pretreatment tumor biopsy (excluding fine needle aspiration and cytology samples) taken after the subject has discontinued sorafenib and within 28 days before the day of first dosing with msc2156119j. from the pretreatment biopsy either a formalin-fixed (formalin fixation is mandatory) paraffin-embedded block with tumor tissue (preferred) or at least 15 unstained slides must be sent to the central laboratory prior to enrollment. an associated pathology report must also be sent with the sample * previously treated with sorafenib for greater than or equal to 4 weeks and discontinued sorafenib treatment at least 14 days prior to day 1 due to either intolerance or radiographic progression * signed and dated informed consent indicating that the subject (or legally acceptable representative if applicable by local laws) has been informed of all the pertinent aspects of the trial prior to enrollment * willingness and ability to comply with scheduled visits, treatment plans, laboratory tests and other trial procedures * life expectancy of at least 3 months as judged by the investigator exclusion criteria: * prior systemic anticancer treatment for advanced hcc (except for sorafenib as described in the inclusion criteria) * prior treatment with any agent targeting the hepatocyte growth factor (hgf)/c-met pathway * local-regional therapy within 4 weeks before day 1 * impaired cardiac function * other protocol defined exclusion criteria could apply

Keywords: hepatocellular carcinoma c-met inhibitor phase 1b sorafenib msc2156119j
effect of heat aplication to patients during cystoscopy procedure

Conditions: Urological Nursing

Summary: this randomized controlled study was planned to determine the effect of hot application, which is one of the non-pharmacological methods that can be applied to reduce pain during the rigid cystoscopy procedure, on pain, anxiety and comfort levels on 62 persons.as a result, it was found that there was a statistically significant difference between the visual comparison scale scores during and after the procedure according to the participants' groups.

this study was planned to determine the effect of hot application, which is one of the non-pharmacological methods that can be applied to reduce pain during the rigid cystoscopy procedure, on pain, anxiety and comfort levels. this study is a randomized controlled experimental study to determine the effect of heat application on patients' pain, anxiety and comfort levels during the cystoscopy procedure. the population of the research consisted of individuals who were hospitalized in the cystoscopy unit of manisa provincial health directorate merkez efendi state hospital between november 2023 - june 2024, and the sample consisted of individuals who met the inclusion criteriaan dagreed to participate in the research. participants (n=62) were randomized into two groups: intervention (n=31) and control group (n=31) in a 1:1 ratio, using random numbers generated by the simple randomization method on the computer. the intervention group consisted of 5 women and 26 men, the control group consisted of 8 women and 23 men, a total of 13 women and 49 men who is over over 18 years the sample group was presented according to the consort diagram. heat application was not applied routinely to the intervention group, and unlike the intervention group, heat application was not applied only with thermophor to the control group. however, the scales and forms were evaluated and blood pressure and pulse rate were measured during the same period. incollecting data; 'individual introduction form', 'information form regarding the cystoscopy procedure', 'visual comparison scale (vas)', 'data recording form', 'state anxiety scale' and 'general comfort scale short form' were used.

Eligibility criteria:
inclusion criteria: rigid (rigid) cystoscopy was performed for diagnosis and / or treatment purposes (bladder tumor). does not require anesthesia. over 18 years old no communication barrier without severe disease cystoscopy for the first time or for control purposes i̇ndividuals who participated in this research for the first time and agreed to participate in the research constituted the inclusion criteria. exclusion criteria: urinary hematuria. urinary tract infection overactive bladder pelvic pain etc. a mental health disease, who had communication problems. under 18 years of age. anesthesia, not agree to participate in the research were excluded from the study.

Keywords: anxiety confort cystoscopy heat application pain bladder tumor
evaluation of efficacy and safety of goff transpancreatic septotomy vs. double wire technique for achieving biliary access in technically challenging ercps

Conditions: Biliary Obstruction; Biliary Stones

Summary: randomized, prospective study evaluating efficacy and safety of goff transpancreatic septotomy vs. double wire technique for achieving biliary access in patients who fail initial cannulation at ercp.

selective placement of a guidewire into the bile duct (biliary cannulation) during endoscopic retrograde cholangiopancreatography (ercp) is necessary for performing therapeutic biliary procedures. the success rate for biliary cannulation by experienced endoscopists during ercp is approximately 85% with standard cannulation techniques. inadvertent placement of the guidewire into the pancreatic duct rather than the bile duct often occurs when attempting selective biliary cannulation in technically challenging cases. when this occurs repeatedly, other approaches may be used to facilitate selective biliary cannulation, but there are few prospective studies evaluating the efficacy and safety of these approaches. here the investigators evaluate two approaches for technically challenging biliary cannulation: one involving maintenance of a wire in the pancreatic duct, followed by repeat attempt at biliary cannulation (double wire technique) and one involving a small incision in the septum adjacent to the pancreas followed by repeat attempt at biliary cannulation (transpancreatic septotomy). this study is a prospective randomized trial comparing the rate of cannulation success, procedure duration and complications following these two approaches.

Eligibility criteria:
inclusion criteria: 1. age 18 and older 2. patient has a clinical indication for ercp 3. willing and able to comply with the study procedures and provide written informed consent to participate in the study. exclusion criteria: 1. age \<18 2. potentially vulnerable subjects including, homeless people, pregnant females, employees and students. 3. complex post-surgical anatomy e.g. billroth type ii anatomy, roux-en-y-gastrojejunostomy 4. prior sphincterotomy or balloon dilation of ampulla 5. thrombocytopenia, coagulopathy, or indication for ongoing anti-coagulation therapy 6. participation in another investigational study that may directly or indirectly affect the results of this study within 30 days prior to the initial visit
a study of soundscapes for patient wellbeing

Conditions: Varicose Veins

Summary: the purpose of this study is to assess the impact of immersive soundscape on patient pain, stress, anxiety, heart rate and blood pressure during an outpatient vascular surgery procedure.

adult (≥18-years-old) patients having outpatient vascular surgery procedures who elect to participate in the study will be randomized to control/ intervention. for control subjects: procedure will be performed in the procedure room with no immersive soundscape. for intervention subjects procedure will be performed in the procedure room with immersive soundscape.

Eligibility criteria:
inclusion criteria: - english-speaking adults exclusion criteria: * patients needing an english interpreter * patients who lack the capacity to provide consent.